| dc.contributor |
Epicentre, Paris, France. msffr.comed@online.com.kh |
|
| dc.creator |
Ferradini, L |
|
| dc.creator |
Laureillard, D |
|
| dc.creator |
Prak, N |
|
| dc.creator |
Ngeth, C |
|
| dc.creator |
Fernandez, M |
|
| dc.creator |
Pinoges, L |
|
| dc.creator |
Puertas, G |
|
| dc.creator |
Taburet, A |
|
| dc.creator |
Ly, N |
|
| dc.creator |
Rouzioux, C |
|
| dc.creator |
Balkan, S |
|
| dc.creator |
Quillet, C |
|
| dc.creator |
Delfraissy, J F |
|
| dc.date |
2007-11-12 |
|
| dc.date.accessioned |
2017-01-31T07:10:17Z |
|
| dc.date.available |
2017-01-31T07:10:17Z |
|
| dc.identifier |
Positive Outcomes of HAART at 24 Months in HIV-Infected Patients in Cambodia. 2007, 21 (17):2293-301 AIDS |
|
| dc.identifier |
0269-9370 |
|
| dc.identifier |
18090277 |
|
| dc.identifier |
10.1097/QAD.0b013e32828cc8b7 |
|
| dc.identifier |
http://hdl.handle.net/10144/19977 |
|
| dc.identifier |
http://fieldresearch.msf.org/msf/handle/10144/19977 |
|
| dc.identifier |
AIDS |
|
| dc.identifier.uri |
http://dspace.mediu.edu.my:8181/xmlui/handle/10144/19977 |
|
| dc.description |
OBJECTIVES: African and Asian cohort studies have demonstrated the feasibility and efficacy of HAART in resource-poor settings. The long-term virological outcome and clinico-immunological criteria of success remain important questions. We report the outcomes at 24 months of antiretroviral therapy (ART) in patients treated in a Médecins Sans Frontières/Ministry of Health programme in Cambodia. METHODS: Adults who started HAART 24 +/- 2 months ago were included. Plasma HIV-RNA levels were assessed by real-time polymerase chain reaction. Factors associated with virological failure were analysed using logistic regression. RESULTS: Of 416 patients, 59.2% were men; the median age was 33.6 years. At baseline, 95.2% were ART naive, 48.9% were at WHO stage IV, and 41.6% had a body mass index less than 18 kg/m. The median CD4 cell count was 11 cells/microl. A stavudine-lamivudine-efavirenz-containing regimen was initiated predominantly (81.0%). At follow-up (median 23.8 months), 350 (84.1%) were still on HAART, 53 (12.7%) had died, six (1.4%) were transferred, and seven (1.7%) were lost to follow-up. Estimates of survival were 85.5% at 24 months. Of 346 tested patients, 259 (74.1%) had CD4 cell counts greater than 200 cells/microl and 306 (88.4%) had viral loads of less than 400 copies/ml. Factors associated with virological failure at 24 months were non-antiretroviral naive, an insufficient CD4 cell gain of less than 350 cells/microl or a low trough plasma ART concentration. In an intention-to-treat analysis, 73.6% of patients were successfully treated. CONCLUSION: Positive results after 2 years of advanced HIV further demonstrate the efficacy of HAART in the medium term in resource-limited settings. |
|
| dc.language |
en |
|
| dc.rights |
Published by Wolters Kluwer Lippincott Williams & Wilkins - Archived on this site by kind permission Wolters Kluwer |
|
| dc.title |
Positive Outcomes of HAART at 24 Months in HIV-Infected Patients in Cambodia. |
|